Eli Lilly Faces SEC Scrutiny Over $165M R&D Acquisition Milestone Payments

Compiled by Tom Li

Recently, Eli Lilly and Company faced charges and质疑from the U.S. Securities and Exchange Commission (SEC) regarding milestone payments of up to $165 million. These payments were derived from several R&D projects acquired during business mergers.

The U.S. SEC stated that the amounts do not comply with the GAAP standards issued by the Financial Accounting Standards Board, and emphasized in the notification letter that these allegations would impact Eli Lilly's earnings per share by approximately $0.15. Therefore, the actual amounts may differ from the company’s current expectations.

Moreover, in the letter from the U.S. SEC, Eli Lilly was also requested to provide unaudited historical financial information related to the acquisition and to publish the relevant information on the investor page of its website. In response, Eli Lilly stated that it is making necessary changes to the presentation of non-GAAP financial metrics in accordance with the guidance provided by the U.S. SEC.

In February 2021, Eli Lilly came under strict scrutiny by the U.S. SEC due to "inappropriate communications" between its former Chief Financial Officer, Josh Smiley, and several employees. Although Smiley's actions were unrelated to financial data, Eli Lilly still had to file a report with the U.S. SEC at the time. Relevant documents revealed that Smiley ultimately forfeited his $1 million cash bonus from 2020 as well as approximately $3 million in shareholder awards and other assets. Additionally, the U.S. SEC confiscated up to $24 million worth of Smiley’s assets.

This move is considered a strong measure by the U.S. government to crack down on violations by pharmaceutical giants. Just two weeks ago, both the U.S. Senate and House of Representatives introduced new legislation aimed at strengthening competition and stimulating innovation within pharmaceutical companies. The bill was ultimately passed mainly due to an investigation by the U.S. House Oversight and Reform Committee into several large pharmaceutical firms, which found evidence suggesting intentional obstruction of generic drugs and biosimilars from entering the market. Among the major pharmaceutical companies criticized were Eli Lilly and Company, Sanofi, Novo Nordisk, and AbbVie.

Reference Source: Eli Lilly Faces $165M in Charges Over R&D Acquisitions in Latest SEC Exchange